Proteon Therapeutics…today announced results from PATENCY-2, its Phase 3 clinical trial of investigational vonapanitase in patients with chronic kidney disease (CKD) undergoing creation of a radiocephalic fistula for hemodialysis. This study did not meet its co-primary endpoints of fistula use for hemodialysis (p=0.328) and secondary patency (p=0.932).
I.e., placebo-like efficacy.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”